# A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

> **NCT03576651** · PHASE1 · COMPLETED · sponsor: **JHL Biotech, Inc.** · enrollment: 154 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **BIOLOGICAL:** JHL1149
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT03576651
- **Lead sponsor:** JHL Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-24
- **Primary completion:** 2018-09-17
- **Final completion:** 2019-12-13
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576651, "A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03576651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*